Lurbinectedin Sequencing Restrictions and Real-World Treatment Patterns in ES-SCLC

Dr. Sands addresses the NCCN footnote stating lurbinectedin cannot be reused after relapse following maintenance use, comparing this to how progression on one PD-L1 inhibitor doesn't necessarily preclude using another. He distinguishes between local progression (where radiating the affected site while continuing systemic therapy makes sense if overall disease control persists) versus multi-site progression indicating true drug resistance requiring discontinuation.

He emphasizes using the best available regimen upfront rather than reserving options, noting lurbinectedin's favorable tolerability profile compares well even without head-to-head randomized data. In second-line settings, response rates of approximately 35% to 36% were observed in phase 2 studies, with particular significance for patients with chemotherapy-free intervals under 90 days showing 19% achieving 6 months disease control, demonstrating a benefit exceeding their platinum response duration.

For patients with greater than 90-day chemotherapy-free intervals, 44% achieved 6 months disease control. Dr. Sands cautions against the logic of "saving" lurbinectedin for patients with poor platinum responses, suggesting patients responding well to platinum might actually benefit most from lurbinectedin. His only caveat involves ensuring adequate recovery of functional status and blood counts before initiating subsequent cytotoxic therapy, avoiding cumulative patient debilitation through overly aggressive sequential treatment without recovery periods.